Related Experiment Video

Updated: Aug 20, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

The role of BRCA1 in the cellular response to chemotherapy

Richard D Kennedy1, Jennifer E Quinn, Paul B Mullan

  • 1Department of Oncology, Cancer Research Centre, The Queen's University of Belfast, Northern Ireland.

Journal of the National Cancer Institute
|November 18, 2004
PubMed

Insights

Loss of BRCA1 gene function in breast and ovarian cancers may predict sensitivity to DNA-damaging chemotherapy. This finding suggests BRCA1 status can guide treatment selection for improved patient outcomes.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Germline mutations in the BRCA1 gene are linked to hereditary breast and ovarian cancers.
  • Reduced BRCA1 expression or function may also contribute to sporadic cancer development.
  • BRCA1 plays a crucial role in DNA damage response, cell cycle regulation, and other cellular processes.

Purpose of the Study:

  • To review preclinical and clinical evidence on the role of BRCA1 function in chemotherapy response for breast and ovarian cancers.
  • To assess whether BRCA1 status can guide the selection of chemotherapeutic agents.

Main Methods:

  • Systematic review of published preclinical and clinical studies.
  • Analysis of evidence linking BRCA1 function levels to chemotherapy sensitivity and resistance.

Main Results:

  • Loss of BRCA1 function is associated with increased sensitivity to DNA-damaging chemotherapy agents.
  • A loss of BRCA1 function may correlate with resistance to spindle poisons.
  • BRCA1's role in DNA repair influences tumor response to various chemotherapies.

Conclusions:

  • BRCA1 functional status is a potential biomarker for predicting chemotherapy response in breast and ovarian cancers.
  • Tailoring chemotherapy based on BRCA1 function could optimize treatment strategies.
  • Further prospective clinical studies are recommended to validate these findings.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...